There are 2934 resources available
5308 - Chemotherapy plus local-regional radiotherapy versus chemotherapy alone in primary metastatic nasopharyngeal carcinoma: a randomized, open-label, phase 3 trial
Presenter: Mingyuan Chen
Session: Proffered Paper – Head and neck cancer
Resources:
Abstract
569 - Pembrolizumab in microsatellite instability high cancers: updated analysis of the phase 2 KEYNOTE-164 and KEYNOTE-158 studies
Presenter: Luis Diaz
Session: Proffered Paper – Immunotherapy of cancer
Resources:
Abstract
3080 - Mutational profile of malignant pleural mesothelioma (MPM) in the phase II RAMES Study
Presenter: Maria Pagano
Session: Proffered Paper 2 – Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma)
Resources:
Abstract
Proffered Paper – Head and neck cancer - Invited Discussant LBA65, 1108O and 1109O
Presenter: Marco Merlano
Session: Proffered Paper – Head and neck cancer
Resources:
Slides
Webcast
Proffered Paper – Immunotherapy of cancer - Invited Discussant 1174O and 1192O
Presenter: Francois Ghiringhelli
Session: Proffered Paper – Immunotherapy of cancer
Resources:
Slides
Webcast
1665 - A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM) – results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
Presenter: Sanjay Popat
Session: Proffered Paper 2 – Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma)
Resources:
Abstract
Slides
Webcast
Proffered Paper 2 – Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma) - Invited Discussant 1843O and 1844O
Presenter: Paul Baas
Session: Proffered Paper 2 – Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma)
Resources:
Slides
Webcast
Introduction
Presenter: Emiliano Calvo
Session: Individualised dosing of commonly used anti-cancer agents
Resources:
Slides
Webcast
Drug-drug interactions: Focus on acid-suppressive agents
Presenter: Ron Mathijssen
Session: Individualised dosing of commonly used anti-cancer agents
Resources:
Slides
Webcast
Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKIs)
Presenter: Markus Joerger
Session: Individualised dosing of commonly used anti-cancer agents
Resources:
Slides
Webcast